(Updates with Biogen's response in the third paragraph and the latest stock moves in the last paragraph.)
Sage Therapeutics (SAGE) said Monday its board rejected Biogen's (BIIB) unsolicited, non-binding proposal to acquire Sage shares not already owned by Biogen for $7.22 per share.
Sage also said its board has started a process to look into strategic alternatives, including a potential business combination or sale. The company said there's no assurance that the review would lead to a transaction or other strategic outcome.
Biogen declined to comment when contacted by MT Newswires.
Sage shares were up 4.7% and Biogen's shares were up 1.9% in recent trading.
Price: 7.44, Change: +0.34, Percent Change: +4.72
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。